A nurse is administering a medication with a half-life of 6 hours. If the initial dose is 800 mg, how much of the medication will remain in the patient's system after 18 hours?

A. Request an order for an antiemetic: Although nausea is a symptom of digoxin toxicity, administering an antiemetic may mask a serious underlying problem. It should not be the first intervention without further assessment of the client’s condition.
B. Check the client's vital signs: Digoxin toxicity can cause bradycardia, hypotension, and arrhythmias. The client's symptoms (nausea, weakness, and visual disturbances) are classic signs of digoxin toxicity. Assessing vital signs is the priority to determine if there is immediate hemodynamic instability, which would guide further urgent interventions.
C. Suggest that the client rests before eating the meal: Fatigue may be related to digoxin toxicity or underlying heart failure, but suggesting rest delays necessary clinical assessment and does not address the potentially serious symptoms.
D. Request a dietitian consult: While nutrition is important for clients with CHF, the presence of nausea, weakness, and visual disturbances suggests possible digoxin toxicity, which requires immediate clinical evaluation not dietary consultation.

A. Donepezil cures Alzheimer's disease: There is currently no cure for Alzheimer's disease. Donepezil does not halt or reverse the disease process; it only manages symptoms for a limited period in some patients.
B. Donepezil prevents the progression of Alzheimer’s disease: Donepezil does not prevent the neurodegenerative progression of Alzheimer’s. The disease will continue to advance despite treatment, although symptoms may be temporarily improved.
C. Donepezil reverses Alzheimer’s disease: Alzheimer's-related brain damage is irreversible, and Donepezil cannot regenerate lost neurons or restore lost function. It may slightly improve cognitive function but cannot reverse the disease process.
D. Donepezil provides symptom relief for Alzheimer’s disease: Donepezil is a cholinesterase inhibitor that increases acetylcholine levels in the brain, temporarily improving cognitive symptoms like memory and awareness. It is approved for symptom management, especially in mild to moderate stages.